Amylyx's Q2 2026 Earnings Call: NDA Timelines, Placebo Assumptions Clash

Date of Call: Aug 6, 2026

Business Commentary:

Progress in Avexatide Development:

• MLX Pharmaceuticals has completed the last patient visit in its pivotal Phase III lucidity trial for Avexatide, with the database expected to lock and top-line data readout anticipated in late August or early September 2026.
• The company is on track with its strategic priorities for Avexatide, including advancing NDA readiness and regulatory preparations for a potential 2027 commercial launch.
• The progress is driven by the trial's design to replicate successful Phase II studies, rigorous patient eligibility assessments, and strong execution by the clinical team.

Financial Position and Cash Runway:

• The company ended the second quarter with $250.8 million in cash and marketable securities, providing an anticipated cash runway into 2028.
• Operating expenses increased by 7% compared to the same period in 2025, primarily due to a decrease in spending related to AMX-35 and an increase in expenses related to Avexatide clinical development.
• This financial position supports continued investment in the pivotal trial and broader pipeline development, ensuring funding through key milestones.

Commercial Preparedness and Market Awareness:

• MLX Pharmaceuticals continues to build commercial readiness, with an estimated U.S. patient population of 160,000 living with post-bariatric hypoglycemia (PBH).
• Market research indicates high intent among endocrinologists to treat PBH with an approved therapy, supported by growing recognition of the condition, including the inclusion of a specific ICD-10 code for PBH in 2027.
• The company has activated a disease state education campaign to increase awareness and understanding of PBH among healthcare professionals and the PBH community.

Pipeline Advancements:

• In addition to Avexatide, MLX is advancing its broader pipeline, including AMX-35 for progressive supranuclear palsy, AMX-114 for ALS, and AMX-318, a long-acting GLP-1 receptor antagonist with an IND filing targeted for 2027.
• The company has entered into a second research collaboration with Gubra to screen and develop peptide candidates for another rare endocrine disease of high unmet need.
• These efforts underscore MLX's commitment to addressing significant unmet needs in rare diseases, with ongoing clinical trials and research collaborations supporting pipeline progression.

Sentiment Analysis:

Overall Tone: Positive

• Management expresses excitement about the pivotal Phase III data readout on track for late August/early September, describes it as an 'exciting time' and notes 'strong execution.' They highlight 'growing recognition' of PBH, 'encouraging' early engagement with healthcare professionals, and confidence in commercial readiness for a potential 2027 launch.

Q&A:

• Question from Seamus Fernandez (Guggenheim): Could you update on when the last patient visit was and the key factors needed to lock the database? Also, provide color on the early access program (EAP) progress and demand.
  Response: Last patient visit was mid-late July; database lock requires diligent data cleaning. EAP is in early days but generating enthusiasm; it includes prior trial participants and those completing the double-blind period.

• Question from Joseph Toome (CD Killen): Does the Phase 3 patient population look similar to prior Phase 2 trials, and what mechanisms were in place to monitor compliance?
  Response: Population is consistent with Phase 2; eligibility was rigorously assessed. Compliance was monitored through site selection, run-in period screening, and ongoing oversight with clinical teams.

• Question from Cody Flory (Evercore ISI): What evidence is needed for a broad PBH label encompassing all surgeries, and what is the realistic treated population from the 160,000 patient estimate?
  Response: Label discussion with FDA is ongoing; a claim for all PBH is strong but FDA could restrict to Roux-en-Y gastric bypass initially, requiring an efficient bridging study. The treated population is substantial, with about 120,000 in the narrower label scenario.

• Question from Jeff Meacham (Citibank): Will pricing differentiate between Level 2 and 3 hypoglycemic events, and are all elements of the NDA filing complete post-Phase 3?
  Response: Pricing will consider analogs in rare and endocrinology; top-line data is the last major piece needed for NDA submission.

• Question from Mark Goodman (The Rink Partners): What is the concentration of PBH patients in specific sites, and what should be expected for the placebo response in the Phase 3 trial?
  Response: Some centers have 50-100 patients; the PBH population is concentrated. Placebo effect is unknown but the study is conservatively powered (90% for 35% treatment effect vs. up to 50% placebo), based on prior trial data showing strong drug effects.

• Question from Rami Kakuta (Life Science Capital): What secondary endpoints will be included in the top-line release, and what is the focus of the new research collaboration with Gubra?
  Response: Top-line data will follow standard practice for rare disease pivotal trials. The new collaboration with Gubra targets another rare endocrine disease with high unmet need, leveraging their peptide expertise.

Contradiction Point 1

Timeline for Database Lock and Top-Line Data

It directly impacts expectations regarding the timeline for critical data milestones, potentially influencing investor expectations and stock price volatility.

What are your key takeaways from the latest earnings report? - Seamus Fernandez (Guggenheim)

2026Q2: blinded database lock and top-line data expected in late August or early September. - Justin Klee(Co-CEO)

What is the status of the last patient visit and the key factors needed to complete database lock? - Seamus Fernandez (Guggenheim)

2026Q2: with top-line data expected late August or early September. - Dr. Camille Bedrosian(CMO) & Justin Klee(Co-CEO)

Contradiction Point 2

Definition of Phase 3 Trial Population

It involves a contradiction on whether the Phase 3 population was consistent with prior studies, impacting the interpretation of trial results and potential label approval.

Joseph Toome (CD Killen) - Joseph Toome (CD Killen)

2026Q2: Designed to be consistent with Phase 2/2B studies. - Dr. Camille Bedrosian(CMO)

Okay, let's see. The user wants me to rewrite the input into a single concise earnings-call question. The input is "How does the Phase 3 patient population compare to prior Phase 2 studies?" First, I need to make sure I understand what an earnings-call question typically looks like. These are usually questions that investors or analysts might ask during a company's earnings call, focusing on financial performance, business strategy, or key metrics that impact the company's value.The original question is about comparing patient populations between Phase 3 and prior Phase 2 studies. That sounds like it's related to a pharmaceutical or biotech company's clinical trial data. In an earnings call context, such a question would likely be about how the results from different trial phases affect the company's outlook, potential drug approval, or market expectations.The user's instruction says to output exactly one line, only the final question text, ending with a question mark if a rewrite is possible. If the input isn't a question, is too vague, or lacks info, output it as-is. Here, the input is a question, so we need to rephrase it into a more concise earnings-call format.The original question is already a question, but maybe it's too technical or not framed in terms of business impact. Let me think. The key here is to connect the patient population comparison to business outcomes. So, instead of just comparing populations, the earnings-call question might focus on how this comparison affects the drug's development timeline, efficacy, or regulatory approval chances.But the user wants it concise. The original question is about Phase 3 vs. Phase 2 patient populations. In earnings calls, they might ask how the results from Phase 3 compare to Phase 2 in terms of key metrics. However, the original question is about the patient population characteristics, not the results. So maybe the question is about the size, demographics, or other patient-related factors in the trials.Wait, the user's example might just need to make it a bit more direct. The original is a valid question, but perhaps the user wants it phrased as a direct question for an earnings call. Let me check the rules again: output exactly one line, only the final question text. The input is a question, so if we can rephrase it into a more concise form that's suitable for an earnings call, we should. Otherwise, leave it as is.The original question is already concise. Maybe it's acceptable as is. But perhaps the user wants to ensure it's phrased in a way that's typical for earnings calls. For example, "How does the Phase 3 patient population compare to prior Phase 2 studies in terms of key metrics?" But the original doesn't specify "key metrics". However, the original question is about the patient population itself, not the results. So maybe the original is already suitable.But the user's instruction says to output exactly one line, only the final question text. If the input is already a clear question, maybe we can leave it as is. However, the user might consider it too vague. Wait, the input is "How does the Phase 3 patient population compare to prior Phase 2 studies?" That's a specific question about patient populations in different trial phases. It's not too vague. It's a valid question that could be asked in an earnings call for a company in clinical trials.But maybe the user wants it rephrased as a more direct question. For example, "What are the key differences between the Phase 3 and prior Phase 2 patient populations?" But the original is already a question. The user's instruction says if the input is a question, and can be rewritten, output the rewritten question. Otherwise, leave as is.So perhaps the original is already a suitable earnings-call question. Therefore, the answer would be the original input. But the user might want to make it more concise. Let me check the original input again. "How does the Phase 3 patient population compare to prior Phase 2 studies?" It's already concise. Maybe the user wants to ensure it's a question that's typical in earnings calls. Alternatively, maybe the user wants to rephrase it to be more about the business impact. For example, "How do the results from Phase 3 compare to Phase 2 studies?" But the original is about patient population, not results.Hmm. Since the original is a clear, concise question about patient populations between trial phases, and it's relevant for a company's drug development progress, which is important in earnings calls, I think it's acceptable as is. Therefore, the output should be the original input, but with a question mark. Wait, the input already ends with a question mark. So the output would be the same as input. But according to the rules, if the input is a question and can be rewritten, output the rewritten version. Otherwise, output as-is. But since the input is already a valid question, maybe no rewrite is needed. However - Joseph To (Citi)

2026Q2: The LUCIDITY population is consistent with phase II studies - Dr. Camille Bedrosian(CMO) & Justin Klee(Co-CEO)

Contradiction Point 3

Timeline and Readiness for NDA Filing

It reflects inconsistencies on when the NDA can be submitted after Phase 3 data, affecting the perceived timeline for regulatory submission and market access.

Jeff Meacham (Citibank) - Jeff Meacham (Citibank)

2026Q2: The Phase 3 top-line data is the final key piece needed for the NDA; other components (preclinical, CMC) are prepared. - Dan Monahan(Chief Commercial Officer)

How will pricing/reimbursement guidelines differentiate between Level 2 and Level 3 hypoglycemic events, and are all elements of the NDA filing (preclinical, CMC, etc.) complete beyond Phase 3? - Seamus Fernandez (Guggenheim)

2026Q1: Working on the NDA now... aims to be as efficient as possible once positive top-line data is available next quarter, with the goal of providing access as promptly as possible. - Josh Cohen(Co-CEO), Justin Klee(Co-CEO)

Contradiction Point 4

Content of Phase 3 Top-Line Data Disclosure

It involves contradictions on what specific data will be included in the top-line release, affecting the clarity and value of the data for investors and stakeholders.

Rami Kakuta (Life Science Capital) - Rami Kakuta (Life Science Capital)

2026Q2: Will include data consistent with standard practice for rare disease Phase 3 trials. - Justin Klee(Co-CEO)

What secondary endpoints in the Phase 3 top-line release are most important to KOLs, and can you provide color on the second research collaboration with Gubra? - Michael DiFiore (Evercore ISI)

2026Q1: Top-line disclosure will focus on the clinically meaningful reduction in Level 2/3 hypoglycemic events (the FDA-agreed primary endpoint)... - Justin Klee(Co-CEO), Camille L. Bedrosian(Chief Medical Officer)

Contradiction Point 5

Assumed Placebo Effect in Phase 3 Trial Design

It involves a contradiction in the rationale for assuming a high placebo response rate, impacting the statistical power and interpretation of the trial results.

Cody Flory (Evercore ISI) - Cody Flory (Evercore ISI)

2026Q2: The Phase 3 trial included only Roux-en-Y gastric bypass patients (per protocol). NDA case will argue for a broad label; FDA could restrict to Roux-en-Y... **Current estimate:** ~120,000 of 160,000 patients have Roux-en-Y gastric bypass. - Justin Klee(Chief Medical Officer)

What evidence package is required for a broad label covering all PBH (including sleeve gastrectomy), and what additional studies are needed if restrictions apply? - Seamus Fernandez (Guggenheim)

20260303-2025 Q4: Regarding powering, while past trials showed minimal placebo response, the Phase III design was strategically conservative, assuming up to 50% placebo effect... - Joshua Cohen(CEO)